Table 3.

Adverse events among patients with BCC treated with PD-1 inhibition

	Grade 1 (%)	Grade 2 (%)	Grade 3 (%)	Grade 4 (%)	Total (%)
Constitutional (fatigue)	9 (31.0)	1 (3.4)	0 (0.0)	0 (0.0)	10 (34.5)
Dermatological (pruritus, rash)	6 (20.7)	1 (3.4)	0 (0.0)	0 (0.0)	7 (24.1)
Endocrine (hypothyroidism)	3 (10.3)	1 (3.4)	0 (0.0)	0 (0.0)	4 (13.8)
Gastrointestinal (diarrhea)	1 (3.4)	1 (3.4)	1 (3.4)	0 (0.0)	3 (10.3)
Musculoskeletal (arthralgia)	0 (0.0)	2 (6.9)	0 (0.0)	0 (0.0)	2 (6.9)
Liver (transaminitis)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.4)	1 (3.4)
Renal (nephritis)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.4)	1 (3.4)
Neurological (encephalitis)	0 (0.0)	1 (3.4)	0 (0.0)	0 (0.0)	1 (3.4)
Infusion reaction	0 (0.0)	1 (3.4)	0 (0.0)	0 (0.0)	1 (3.4)

BCC, basal cell carcinoma.